Lung Cancer News and Research

Latest Lung Cancer News and Research

Short-term use of folic acid supplements unlikely to increase cancer risk

...

25 Jan 2013

People living in the e-waste village more likely to develop lung cancer

Residents living near an e-waste recycling site in China face elevated risks of lung cancer, according to a recent study co-authored by Oregon State University researchers.

24 Jan 2013

MD Anderson - Orlando first in Central Florida to offer pilot lung cancer screening program

One year after MD Anderson Cancer Center Orlando launched a pilot lung cancer screening program for patients most at risk for developing the disease, such screenings are now being recommended by the American Cancer Society.

23 Jan 2013

Smoking cessation helps prevent cancer relapse after surgery

Lung and head and neck cancer patients who smoked before surgery are more likely to relapse than those who had quit before surgery, Moffitt Cancer Center researchers say. They found that smoking-relapse prevention interventions are needed immediately after surgery to help prevent relapse.

23 Jan 2013

New special issue explores link between evolution and the body's fight against cancer

Over 500 billion cells in our bodies will be replaced daily, yet natural selection has enabled us to develop defenses against the cellular mutations which could cause cancer. It is this relationship between evolution and the body's fight against cancer which is explored in a new special issue of the Open Access journal Evolutionary Applications.

22 Jan 2013

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

22 Jan 2013

mTorc1 promotes growth of inflammation-associated colon and gastric cancers

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a new treatment for these diseases.

18 Jan 2013

Report: Cancer death rates decline 20% from its peak in 1991

As of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately 1.2 million deaths from cancer, 152,900 of these in 2009 alone. These figures come from the American Cancer Society's annual Cancer Statistics report, one of the most widely-cited medical publications in the world.

17 Jan 2013

Dietary factors explain most variation in vitamin D status in infants

Research shows that vitamin D supplementation and cow’s milk intake have the greatest influence on 25–hydroxyvitamin D levels in healthy children aged 1–5 years.

17 Jan 2013

Quarter of incident lung cancer slow growing or indolent

A quarter of incident lung cancers are slow growing or indolent, and may be overdiagnosed, suggest results from sequential low-dose computed tomography screening.

17 Jan 2013

FDA clears Sanovas’ Vas Zeppelin Smart Catheter to treat chronic pulmonary diseases, lung cancer

Sanovas Inc., a life science technology company developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that it has filed with the U.S. Food and Drug Administration for clearance of the company's Vas Zeppelin Smart Catheter for the treatment of chronic pulmonary diseases and lung cancer.

17 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.

17 Jan 2013

Study: Patients with EGFR exon 20 insertions need targeted therapies

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

16 Jan 2013

Berries help women beat heart attack risk

Regular consumption of anthocyanin-rich strawberries and blueberries may help prevent heart attacks in young women, suggest study findings.

16 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013